EFFECTIVENESS AND TOXICITY OF PEGYLATED LIPOSOMAL DOXORUBICIN FOR ADVANCED OVARIAN CANCER

被引：0
|
作者：
Sequeira, I. [1 ]
Simas, A. [1 ]
Brandao, M. [1 ]
Savva-Bordalo, J. [1 ]
Pereira, D. [1 ]
机构：
[1] Inst Portugues Oncol Porto Francisco Gentil, Med Oncol, Oporto, Portugal
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2015年 / 25卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ESGO-0929
引用
下载
收藏
页码：1491 / 1491
页数：1
相关论文
共 50 条
  • [31] Efficacy and toxicity of extended duration pegylated liposomal doxorubicin (PLD) in women with recurrent epithelial ovarian cancer
    Chambers, L. Moulton
    Pendlebury, A. B.
    Yao, M.
    Rose, P. G.
    DeBernardo, R.
    GYNECOLOGIC ONCOLOGY, 2020, 159 : 107 - 108
  • [32] Effectiveness of pegylated liposomal doxorubicin maintenance therapy for platinum-sensitive recurrent epithelial ovarian cancer
    Blake, E. A.
    Mostofizadeh, S.
    Bradley, C. A.
    Pham, H. Q.
    Yessaian, A.
    Roman, L. D.
    Muggia, F. M.
    Garcia, A.
    Matsuo, K.
    GYNECOLOGIC ONCOLOGY, 2018, 149 : 49 - 49
  • [33] A phase I study of combined trabectedin and pegylated liposomal doxorubicin therapy for advanced relapsed ovarian cancer
    Shunji Takahashi
    Munetaka Takekuma
    Kenji Tamura
    Kazuhiro Takehara
    Hiroyuki Nomura
    Makiko Ono
    Mayu Yunokawa
    Daisuke Aoki
    International Journal of Clinical Oncology, 2021, 26 : 1977 - 1985
  • [34] Role of pegylated liposomal doxorubicin (Caelyx) in the treatment of relapsing ovarian cancer
    Eva Perez-Lopez, Maria
    Curiel, Teresa
    Garcia Gomez, Jesus
    Jorge, Monica
    ANTI-CANCER DRUGS, 2007, 18 (05) : 611 - 617
  • [35] Pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients
    Gorumlu, G.
    Kucukzeybek, Y.
    Kemal-Gul, M.
    Karaca, B.
    Cosan-Terek, M.
    Karabulut, B.
    Sanli, U. A.
    Akman, L.
    Ozsaran, A.
    Dikmen, Y.
    Uslu, R.
    JOURNAL OF BUON, 2008, 13 (03): : 349 - 352
  • [36] Pegylated liposomal doxorubicin (CAELYX®) in patients with advanced ovarian cancer: results of a German multicenter observational study
    Jalid Sehouli
    O. Camara
    M. Schmidt
    S. Mahner
    G. Seipelt
    B. Otremba
    B. Schmalfeldt
    H. Tesch
    C. Lorenz-Schlüter
    G. Oskay-Özcelik
    Cancer Chemotherapy and Pharmacology, 2009, 64 : 585 - 591
  • [37] A phase I study of combined trabectedin and pegylated liposomal doxorubicin therapy for advanced relapsed ovarian cancer
    Takahashi, Shunji
    Takekuma, Munetaka
    Tamura, Kenji
    Takehara, Kazuhiro
    Nomura, Hiroyuki
    Ono, Makiko
    Yunokawa, Mayu
    Aoki, Daisuke
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (10) : 1977 - 1985
  • [38] Pegylated liposomal doxorubicin (CAELYXA®) in patients with advanced ovarian cancer: results of a German multicenter observational study
    Sehouli, Jalid
    Camara, O.
    Schmidt, M.
    Mahner, S.
    Seipelt, G.
    Otremba, B.
    Schmalfeldt, B.
    Tesch, H.
    Lorenz-Schlueter, C.
    Oskay-Oezcelik, G.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 64 (03) : 585 - 591
  • [39] Phase 2 trial of pegylated liposomal doxorubicin in advanced endometrial cancer
    Escobar, PF
    Markman, M
    Zanotti, K
    Webster, K
    Belinson, J
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2003, 129 (11) : 651 - 654
  • [40] Phase 2 trial of pegylated liposomal doxorubicin in advanced endometrial cancer
    Pedro F. Escobar
    Maurie Markman
    Kristine Zanotti
    Kenneth Webster
    Jerome Belinson
    Journal of Cancer Research and Clinical Oncology, 2003, 129 : 651 - 654
12345